Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study

References

• Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am. Fam. Physician75(12), 1821–1829 (2007).
   PubMed Web of Science ®Google Scholar
• Remington GJ, Collins A. Video workshop: an educational intervention to enhance compliance in schizophrenia. Presented at: Research Program and Abstracts of the 53rd Annual Meeting of the American Psychiatric Association Institute on Psychiatric Services. Orlando, FL, USA, 10–14 October 2001.
   Google Scholar
• Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res.161(2), 235–247 (2008).
   PubMed Web of Science ®Google Scholar
• Hogarty GE, Schooler NR, Ulrich R et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch. Gen. Psychiatry36(12), 1283–1294 (1979).
   PubMed Web of Science ®Google Scholar
• Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J. Psychiatr. Res.32(3–4), 243–250 (1998).
   PubMed Web of Science ®Google Scholar
• Marland GR. Atypical neuroleptics: autonomy and compliance? J. Adv. Nurs.29(3), 615–622 (1999).
   PubMed Web of Science ®Google Scholar
• Kemp RA, David AS. Insight and adherence to treatment in psychotic disorders. Br. J. Hosp. Med.54(5), 222–227 (1995).
   PubMed Web of Science ®Google Scholar
• Möller HJ. Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur. Psychiatry20(5–6), 379–385 (2005).
   PubMed Web of Science ®Google Scholar
• Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Can. J. Psychiatry40(3 Suppl. 1), S5–S11 (1995).
   PubMed Web of Science ®Google Scholar
• Barnes TR, Curson DA. Long-term depot antipsychotics: a risk–benefit assessment. Drug Saf.10(6), 464–479 (1994).
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical guideline 1. NICE, London, UK (2002).
   Google Scholar
• Serretti A, De Ronchi D, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr. Med. Chem.11(3), 343–358 (2004).
   PubMed Web of Science ®Google Scholar
• Möller HJ. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs17(11), 793–823 (2003).
   PubMed Web of Science ®Google Scholar
• Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet361(9369), 1581–1589 (2003).
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 study group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med.346(1), 16–22 (2002).
   PubMed Web of Science ®Google Scholar
• Moore DB, Kelly DL, Sherr JD et al. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am. J. Health Syst. Pharm.55(24 Suppl. 4), S17–S19 (1998).
   Web of Science ®Google Scholar
• Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R. D.6(3), 129–137 (2005).
   PubMedGoogle Scholar
• Medori R, Mannaert E, Gründer G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long acting injectable. Eur. Neuropsychopharmacol.16(4), 233–240 (2006).
   PubMed Web of Science ®Google Scholar
• Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann. Pharmacother.38(12), 2122–2127 (2004).
   PubMed Web of Science ®Google Scholar
• Knox ED, Stinmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin. Ther.26(12), 1994–2002 (2004).
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Jarboe K, Bossie CA et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int. Clin. Psychopharmacol.20(4), 213–221 (2005).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Association, Washington, DC, USA (1994).
   Google Scholar
• Bai YM, Ting Chen T, Chen JY et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J. Clin. Psychiatry68(8), 1218–1225 (2007).
   PubMed Web of Science ®Google Scholar
• Kiivet RA, Llerena A, Dahl ML et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br. J. Clin. Pharmacol.40(5), 467–476 (1995).
   PubMed Web of Science ®Google Scholar
• Thusholt FJ, Jensen EO, Knop J et al. Use of psychiatric emergency clinics in Copenhagen and Frederiksberg by schizophrenic patients. Ugeskr. Laeger.155(19), 1459–1463 (1993).
   PubMedGoogle Scholar
• Sanguinetti VR, Samuel SE, Schwartz SL, Robeson MR. Retrospective study of 2,200 involuntary psychiatric admissions and readmissions. Am. J. Psychiatry153(3), 392–396 (1996).
   PubMed Web of Science ®Google Scholar
• De las Cuevas C, Sanz EJ. Polypharmacy in psychiatric practice in the Canary Islands. BMC Psychiatry4, 18 (2004).
   PubMedGoogle Scholar
• Faries D, Ascher-Svanum H, Zhu B et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry5, 26 (2005).
   PubMed Web of Science ®Google Scholar
• Santamaria B, Perez M, Montero D et al. Use of antipsychotic agents in Spain through 1985–2000. Eur. Psychiatry17(8), 471–476 (2002).
   PubMed Web of Science ®Google Scholar
• Mauri MC, Turner M, Volonteri LS, Medori R, Maier W. Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg. Int. J. Psychiatry Clin. Pract.13(1), 36–47 (2009).
   PubMed Web of Science ®Google Scholar
• Möller HJ, Llorca PM, Sacchetti E, Matin SD, Medori R, Parellada E. StoRMi study group: efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int. Clin. Psychopharmacol.20(3), 121–130 (2005).
   PubMed Web of Science ®Google Scholar
• Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim. Care Companion J. Clin. Psychiatry7(3), 121–129 (2005).
   PubMedGoogle Scholar
• Bowers L, Callaghan P, Clark N, Evers C. Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe. Eur. J. Clin. Pharmacol.60(1), 29–35 (2004).
   PubMed Web of Science ®Google Scholar
• Edlinger M, Hausmann A, Kemmler G et al. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr. Res.77(1), 25–34 (2005).
   PubMed Web of Science ®Google Scholar
• Llorca PM, Bouhours P, Moreau-Mallet V. Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone. Encephale34(2), 170–178 (2008).
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic schizophrenia treatment adherence registry (e-STAR). Eur. Psychiatry24(5), 287–296 (2009).
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; on behalf of the e-STAR Study Group. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl. Health Econ. Health Policy6(1), 41–53 (2008).
   PubMedGoogle Scholar
• Vicente J, Hernández H, De la Gándara J. Tratamiento con risperidona de liberación prolongada en pacientes hospitalizados por trastornos psicóticos. Psiq. Biol.13(2), 47–52 (2006).
   Google Scholar